Fremont, Calif. – Verseon will reveal the latest data on pharmacological safety assessment and the establishment of dose response in preclinical efficacy models on its new class of anticoagulants with lower bleeding liability at a presentation at the Bio Convention meeting on June 7th in San Francisco.

These novel small-molecule direct thrombin inhibitors act through reversible covalent inhibition, a unique mode of action that leads to novel pharmacology, including lower bleeding liability as seen in multiple preclinical tests. In addition to efficacy and lower bleeding risk, Verseon's new class of anticoagulants also has pharmacokinetic properties suitable for oral dosing.

Dr. David Kita, co-founder and Vice President of Research and Development, who will be presenting the data, commented, "This promising new data will form an important part of our upcoming IND (Investigational New Drug) filings for this program."

Verseon's new class of anticoagulants are part of a growing portfolio of drug programs being developed with the aid of the company's proprietary, computational drug discovery platform.

About Verseon

Verseon is a technology-based pharmaceutical company that employs its proprietary, computational drug discovery platform to develop novel therapeutics for today's challenging diseases. The Company is applying its platform to a growing drug pipeline and currently has three active drug programs in the areas of anticoagulation, diabetic macular edema, and solid tumor cancers.